Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTOS 2023 | Botensilimab and balstilimab in refractory metastatic sarcoma

Breelyn Wilky • 9 Nov 2023
CTOS 2023
Sarcoma Antibodies Balstilimab Botensilimab Checkpoint Inhibitors

Breelyn Wilky, MD, University of Colorado Anschutz Medical Campus, Aurora, CO, discusses findings from a Phase Ia/b trial of botensilimab and balstilimab in patients with refractory metastatic sarcoma (NCT03860272). Addition of botensilimab resulted in more durable progression-free survival across different sarcoma subtypes such as angiosarcoma and leiomyosarcoma, which has been thought to be an immunologically cold tumor. This interview took place at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting in Dublin, Ireland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Breelyn Wilky

3:07
Doxorubicin with zalifrelimab and balstilimab in soft tissue sarcomas
Breelyn Wilky • 9 Nov 2023
5:03
ESMO 2023 sarcoma updates: MEDISARC and TOMAS2
Breelyn Wilky • 9 Nov 2023

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals